Sophiris Bio Cmn (SPHS) 2.44 $SPHS
Drugs - Generic Stocks Technical Snapshot - Sophiris Bio, Neurocrine Biosciences, Lannett, and Supernus Pharma
PR Newswire - Tue Jun 28, 7:25AM CDT
On Monday, June 27, 2016, the NASDAQ Composite ended the trading session at 4,594.44, down 2.41%; the Dow Jones Industrial Average lost 1.50% to finish at 17,140.24; and the S&P 500 closed at 2,000.54, down 1.81%. Stock-Callers.com has initiated coverage on the following equities: Sophiris Bio Inc. (NASDAQ: SPHS), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Lannett Company Inc. (NYSE: LCI), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN). Learn more about these stocks by accessing their free trade alerts at:
LCI: 24.59 (-0.10), NBIX: 48.58 (+0.53), SPHS: 2.44 (-0.05), SUPN: 21.11 (+0.51)
Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer
PR Newswire - Thu Jun 09, 3:00PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced the biopsy results from all 18 patients enrolled in the Phase 2a proof of concept study of topsalysin in localized prostate cancer. The one-time administration of topsalysin was well tolerated with no serious adverse events and no new safety signals being reported. Topsalysin demonstrated an ability to ablate tumor cells in 50 percent of patients (9/18 patients) six months after treatment in a patient population with pre-identified, clinically significant prostate cancer. The results support advancing topsalysin into a Phase 2 study to confirm dose and optimize delivery.
SPHS: 2.44 (-0.05)
Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights
PR Newswire - Mon May 16, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three months ended March 31, 2016.
SPHS: 2.44 (-0.05)
Sophiris Bio Engages Oppenheimer & Co. to Advise on Strategic Opportunities
PR Newswire - Thu May 12, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that it has engaged Oppenheimer & Co. Inc. as its financial advisor to assist with evaluation of strategic alternatives to advance the development of topsalysin and enhance shareholder value, including potential partnering arrangements, financings or a strategic transaction.
SPHS: 2.44 (-0.05)
Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering
PR Newswire - Fri May 06, 4:30PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that it is raising approximately $5 million at a price of $1.40 per share. Additionally, for each share of common stock purchased, the investor will receive a warrant to purchase one-half of a share of common stock of the Company at a price of $1.40 per full share for a period of five years from closing.
SPHS: 2.44 (-0.05)
Sophiris Bio to Present at Bloom Burton & Co. Healthcare Investor Conference
PR Newswire - Thu Apr 28, 3:00PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview and review recent clinical data at the 2016 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Monday May 3, 2016 at 4:00 p.m. Eastern Time.
SPHS: 2.44 (-0.05)
Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights
PR Newswire - Wed Mar 23, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three months and year ended December 31, 2015.
SPHS: 2.44 (-0.05)
Sophiris Bio to Present at BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 3:01PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing topsalysin for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview and review recent clinical data at the 18th Annual BIO CEO & Investor Conference. The presentation is scheduled for Tuesday, February 9, 2016 at 10:00 a.m. ET in New York City.
SPHS: 2.44 (-0.05)
Sophiris Bio Inc. Potential FDA Decision Around the Corner - Brief Report
ACCESSWIRE - Tue Jan 05, 12:44PM CST
SAN DIEGO, CA / ACCESSWIRE / January 5, 2016 / Sophiris Bio Inc. (NASDAQ: SPHS) a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, recently announced financial results for the three and nine months ended September 30, 2015 and business highlights. The Company reported that it will announce initial findings from a Phase 2a trial for the proof of concept for its flagship candidate drug, PRX302. A total of 17 patients with clinically significant, localized low to intermediate risk prostate cancer have been enrolled in the ongoing Phase 2a proof of concept study. The study utilizes previously obtained MRI images mapped to real time 3D ultrasound to target the delivery of PRX302 directly into and around a pre-identified clinically significant tumor. The Company expects to have initial data on histological and MRI changes after six months for approximately half the patients in early 2016 and final data on all patients in the second quarter of 2016.
SPHS: 2.44 (-0.05)
Identifying Opportunity, Placing Risk - Analyst Notes on Five Star Quality Care, Senomyx, Ring Energy and Sophiris Bio
ACCESSWIRE - Fri Dec 18, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Five Star Quality Care Inc. (NYSE: FVE), Senomyx Inc. (NASDAQ: SNMX), Ring Energy Inc. (NYSE: REI) and Sophiris Bio Inc. (NASDAQ: SPHS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FVE: 2.36 (+0.04), SPHS: 2.44 (-0.05), REI: 8.42 (-0.19), SNMX: 2.49 (+0.05)
World Benign Prostatic Hyperplasia Therapeutics Pipeline Review 2015 - 25 Companies & 36 Drug Profiles
M2 - Mon Dec 14, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/46clxb/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - BCWorld Pharm Co. Ltd. - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Dongkook Pharmaceutical Co., Ltd. - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Monosol Rx, LLC - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm. Co., Ltd. Drug Profiles - (dutasteride tadalafil) - (solifenacin succinate tamsulosin hydrochloride) - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BCWPE-004 - BL-214 - CKD-902 - ESN-364 - fexapotide triflutate - HCP-1303 - HIP-1402 - INT-0031 - L-1AD3 - MCS-2 - Micselon - NCE-403 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - tadalafil - talaporfin sodium - tamsulosin hydrochloride CR - tamsulosin hydrochloride DR - tertomotide - topsalysin - udenafil - YBH-1603 For more information visit http://www.researchandmarkets.com/research/46..._prostatic
SPHS: 2.44 (-0.05), NYMX: 3.36 (+0.14)
Sophiris Bio Reports Third Quarter Financial Results and Business Highlights
PR Newswire - Mon Nov 16, 3:01PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and nine months ended September 30, 2015.
SPHS: 2.44 (-0.05)
Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint
PR Newswire - Tue Nov 10, 7:18AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced final results from its Phase 3 "PLUS-1" study of PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). PRX302 demonstrated a statistically significant improvement in International Prostate Symptom Score (IPSS) total score from baseline over 12 months compared to the vehicle-only control group (7.60 vs. 6.58 point overall improvement; p = 0.043), the primary endpoint of the study. PRX302 continues to demonstrate a favorable safety profile, with no evidence of any treatment related sexual or cardiovascular side effects.
SPHS: 2.44 (-0.05)
Versartis names Dr Lars Ekman as global development advisor
M2 - Fri Sep 11, 4:58AM CDT
Biopharmaceutical company Versartis (NasdaqGS:VSAR) revealed on Thursday that it has appointed Lars Ekman, MD, PhD, as its global development advisor.
VSAR: 10.60 (+0.56), SPHS: 2.44 (-0.05), ONCE: 55.43 (+1.38)
Sophiris Bio Reports Second Quarter Financial Results
BusinessWire - Thu Aug 13, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and six months ended June 30, 2015.
SPHS: 2.44 (-0.05)
Drugs - Generic Equities Coverage -- Oculus Innovative Sciences, Medicines, Supernus Pharma, Sophiris Bio, and Rigel Pharma
PR Newswire - Wed Aug 05, 8:35AM CDT
Equity Research Institute has initiated coverage on the following equities: Oculus Innovative Sciences Inc. (NASDAQ: OCLS), The Medicines Company (NASDAQ: MDCO), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), Sophiris Bio Inc. (NASDAQ: SPHS), and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Free research report on Oculus Innovative Sciences can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=OCLS On Tuesday, August 04, 2015, the NASDAQ Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial Average lost 0.27%, to finish the day at 17,550.69, and the S&P 500 closed at 2,093.32, down 0.22%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SPHS: 2.44 (-0.05), MDCO: 34.90 (+0.51), SUPN: 21.11 (+0.51), RIGL: 2.25 (+0.04), OCLS: 4.32 (-0.06)
Sophiris Bio to Present at the LD Micro Invitational Conference
BusinessWire - Wed May 27, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris" , a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the LD Micro Invitational Conference. The presentation is scheduled for Tuesday, June 2, 2015 at 11:30 a.m. PDT in Los Angeles.
SPHS: 2.44 (-0.05)
Sophiris Bio admits first patients under Phase 2a proof of concept study of PRX302 in prostate cancer
M2 - Wed May 27, 4:17AM CDT
Biopharmaceutical company Sophiris Bio (NasdaqGM:SPHS) said on Tuesday that it has dosed the first patients in a Phase 2a proof of concept trial of PRX302 as a treatment for localized low to intermediate risk prostate cancer, the second most common form of cancer in men in the US with an estimated 220,800 new cases in 2015.
SPHS: 2.44 (-0.05)
Drugs - Generic Stocks Technical Snapshot - Sophiris Bio, Neurocrine Biosciences, Lannett, and Supernus Pharma
PR Newswire - Tue Jun 28, 7:25AM CDT
On Monday, June 27, 2016, the NASDAQ Composite ended the trading session at 4,594.44, down 2.41%; the Dow Jones Industrial Average lost 1.50% to finish at 17,140.24; and the S&P 500 closed at 2,000.54, down 1.81%. Stock-Callers.com has initiated coverage on the following equities: Sophiris Bio Inc. (NASDAQ: SPHS), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Lannett Company Inc. (NYSE: LCI), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN). Learn more about these stocks by accessing their free trade alerts at:
LCI: 24.59 (-0.10), NBIX: 48.58 (+0.53), SPHS: 2.44 (-0.05), SUPN: 21.11 (+0.51)
Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer
PR Newswire - Thu Jun 09, 3:00PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced the biopsy results from all 18 patients enrolled in the Phase 2a proof of concept study of topsalysin in localized prostate cancer. The one-time administration of topsalysin was well tolerated with no serious adverse events and no new safety signals being reported. Topsalysin demonstrated an ability to ablate tumor cells in 50 percent of patients (9/18 patients) six months after treatment in a patient population with pre-identified, clinically significant prostate cancer. The results support advancing topsalysin into a Phase 2 study to confirm dose and optimize delivery. SPHS: 2.44 (-0.05)
Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights
PR Newswire - Mon May 16, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three months ended March 31, 2016. SPHS: 2.44 (-0.05)
Sophiris Bio Engages Oppenheimer & Co. to Advise on Strategic Opportunities
PR Newswire - Thu May 12, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that it has engaged Oppenheimer & Co. Inc. as its financial advisor to assist with evaluation of strategic alternatives to advance the development of topsalysin and enhance shareholder value, including potential partnering arrangements, financings or a strategic transaction. SPHS: 2.44 (-0.05)
Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering
PR Newswire - Fri May 06, 4:30PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that it is raising approximately $5 million at a price of $1.40 per share. Additionally, for each share of common stock purchased, the investor will receive a warrant to purchase one-half of a share of common stock of the Company at a price of $1.40 per full share for a period of five years from closing. SPHS: 2.44 (-0.05)
Sophiris Bio to Present at Bloom Burton & Co. Healthcare Investor Conference
PR Newswire - Thu Apr 28, 3:00PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview and review recent clinical data at the 2016 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Monday May 3, 2016 at 4:00 p.m. Eastern Time. SPHS: 2.44 (-0.05)
Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights
PR Newswire - Wed Mar 23, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three months and year ended December 31, 2015. SPHS: 2.44 (-0.05)
Sophiris Bio to Present at BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 3:01PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing topsalysin for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview and review recent clinical data at the 18th Annual BIO CEO & Investor Conference. The presentation is scheduled for Tuesday, February 9, 2016 at 10:00 a.m. ET in New York City. SPHS: 2.44 (-0.05)
Sophiris Bio Inc. Potential FDA Decision Around the Corner - Brief Report
ACCESSWIRE - Tue Jan 05, 12:44PM CST
SAN DIEGO, CA / ACCESSWIRE / January 5, 2016 / Sophiris Bio Inc. (NASDAQ: SPHS) a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, recently announced financial results for the three and nine months ended September 30, 2015 and business highlights. The Company reported that it will announce initial findings from a Phase 2a trial for the proof of concept for its flagship candidate drug, PRX302. A total of 17 patients with clinically significant, localized low to intermediate risk prostate cancer have been enrolled in the ongoing Phase 2a proof of concept study. The study utilizes previously obtained MRI images mapped to real time 3D ultrasound to target the delivery of PRX302 directly into and around a pre-identified clinically significant tumor. The Company expects to have initial data on histological and MRI changes after six months for approximately half the patients in early 2016 and final data on all patients in the second quarter of 2016.
SPHS: 2.44 (-0.05)
Identifying Opportunity, Placing Risk - Analyst Notes on Five Star Quality Care, Senomyx, Ring Energy and Sophiris Bio
ACCESSWIRE - Fri Dec 18, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Five Star Quality Care Inc. (NYSE: FVE), Senomyx Inc. (NASDAQ: SNMX), Ring Energy Inc. (NYSE: REI) and Sophiris Bio Inc. (NASDAQ: SPHS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FVE: 2.36 (+0.04), SPHS: 2.44 (-0.05), REI: 8.42 (-0.19), SNMX: 2.49 (+0.05)
World Benign Prostatic Hyperplasia Therapeutics Pipeline Review 2015 - 25 Companies & 36 Drug Profiles
M2 - Mon Dec 14, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/46clxb/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - BCWorld Pharm Co. Ltd. - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Dongkook Pharmaceutical Co., Ltd. - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Monosol Rx, LLC - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm. Co., Ltd. Drug Profiles - (dutasteride tadalafil) - (solifenacin succinate tamsulosin hydrochloride) - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BCWPE-004 - BL-214 - CKD-902 - ESN-364 - fexapotide triflutate - HCP-1303 - HIP-1402 - INT-0031 - L-1AD3 - MCS-2 - Micselon - NCE-403 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - tadalafil - talaporfin sodium - tamsulosin hydrochloride CR - tamsulosin hydrochloride DR - tertomotide - topsalysin - udenafil - YBH-1603 For more information visit http://www.researchandmarkets.com/research/46..._prostatic
SPHS: 2.44 (-0.05), NYMX: 3.36 (+0.14)
Sophiris Bio Reports Third Quarter Financial Results and Business Highlights
PR Newswire - Mon Nov 16, 3:01PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and nine months ended September 30, 2015. SPHS: 2.44 (-0.05)
Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint
PR Newswire - Tue Nov 10, 7:18AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced final results from its Phase 3 "PLUS-1" study of PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). PRX302 demonstrated a statistically significant improvement in International Prostate Symptom Score (IPSS) total score from baseline over 12 months compared to the vehicle-only control group (7.60 vs. 6.58 point overall improvement; p = 0.043), the primary endpoint of the study. PRX302 continues to demonstrate a favorable safety profile, with no evidence of any treatment related sexual or cardiovascular side effects. SPHS: 2.44 (-0.05)
Versartis names Dr Lars Ekman as global development advisor
M2 - Fri Sep 11, 4:58AM CDT
Biopharmaceutical company Versartis (NasdaqGS:VSAR) revealed on Thursday that it has appointed Lars Ekman, MD, PhD, as its global development advisor.
VSAR: 10.60 (+0.56), SPHS: 2.44 (-0.05), ONCE: 55.43 (+1.38)
Sophiris Bio Reports Second Quarter Financial Results
BusinessWire - Thu Aug 13, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and six months ended June 30, 2015. SPHS: 2.44 (-0.05)
Drugs - Generic Equities Coverage -- Oculus Innovative Sciences, Medicines, Supernus Pharma, Sophiris Bio, and Rigel Pharma
PR Newswire - Wed Aug 05, 8:35AM CDT
Equity Research Institute has initiated coverage on the following equities: Oculus Innovative Sciences Inc. (NASDAQ: OCLS), The Medicines Company (NASDAQ: MDCO), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), Sophiris Bio Inc. (NASDAQ: SPHS), and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Free research report on Oculus Innovative Sciences can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=OCLS On Tuesday, August 04, 2015, the NASDAQ Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial Average lost 0.27%, to finish the day at 17,550.69, and the S&P 500 closed at 2,093.32, down 0.22%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SPHS: 2.44 (-0.05), MDCO: 34.90 (+0.51), SUPN: 21.11 (+0.51), RIGL: 2.25 (+0.04), OCLS: 4.32 (-0.06)
Sophiris Bio to Present at the LD Micro Invitational Conference
BusinessWire - Wed May 27, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the LD Micro Invitational Conference. The presentation is scheduled for Tuesday, June 2, 2015 at 11:30 a.m. PDT in Los Angeles. SPHS: 2.44 (-0.05)
Sophiris Bio admits first patients under Phase 2a proof of concept study of PRX302 in prostate cancer
M2 - Wed May 27, 4:17AM CDT
Biopharmaceutical company Sophiris Bio (NasdaqGM:SPHS) said on Tuesday that it has dosed the first patients in a Phase 2a proof of concept trial of PRX302 as a treatment for localized low to intermediate risk prostate cancer, the second most common form of cancer in men in the US with an estimated 220,800 new cases in 2015.
SPHS: 2.44 (-0.05)
